
Opinion|Videos|July 16, 2024
BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment
Heidi Crayton, MD, discusses the rationale for investigating Bruton tyrosine kinase inhibitors (BTKis) as a treatment for patients with multiple sclerosis and the current stage of development for evobrutinib, tolebrutinib, and other BTKis.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What was the rationale for the investigation of Bruton tyrosine kinase inhibitors (BTKis) for use as treatment in patients with multiple sclerosis (MS)?
- What is the stage in development for evobrutinib, tolebrutinib and other BTKis?
- How might these therapies fit into treatment algorithms for different types of MS?
- How do payers see these therapies being integrated into treatment algorithms?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
CVS Pharmacy Completes Acquisition of Select Rite Aid Locations
2
Increased Risk of Recurrence in NSCLC Found After Preoperative PTNB
3
Accountable Care: Not Just for the Healthiest Patients
4
Novel Machine Learning Model Improves MASLD Detection in Type 2 Diabetes
5